| CTRI Number |
CTRI/2018/03/012400 [Registered on: 07/03/2018] Trial Registered Retrospectively |
| Last Modified On: |
27/02/2018 |
| Post Graduate Thesis |
No |
| Type of Trial |
Interventional |
|
Type of Study
|
Ayurveda |
| Study Design |
Single Arm Study |
|
Public Title of Study
|
Management of Arthritis pain by a Polyherbal medicine. |
|
Scientific Title of Study
|
Clinical Evaluation of Harijiwan Oil in the treatment of Sandhivata (Osteoarthritis) |
| Trial Acronym |
|
|
Secondary IDs if Any
|
| Secondary ID |
Identifier |
| NIL |
NIL |
|
|
Details of Principal Investigator or overall Trial Coordinator (multi-center study)
|
| Name |
ProfDrSudarsan Behera |
| Designation |
Principal and H.O.D., Kayachiktsa |
| Affiliation |
Gopabandhu Ayurveda Mahavidyalaya, Puri |
| Address |
At - VIP Road, Near Jhadeswari Temple, Puri - 2, Odisha
Head of Department, Kayachiktsa, Room no. 6, Gopabandhu Ayurveda Mahavidyalaya, Puri
Puri ORISSA 752002 India |
| Phone |
9437199477 |
| Fax |
|
| Email |
prinicipalgampuri@gmail.com |
|
Details of Contact Person Scientific Query
|
| Name |
ProfDrSudarsan Behera |
| Designation |
Principal and H.O.D., Kayachiktsa |
| Affiliation |
Gopabandhu Ayurveda Mahavidyalaya, Puri |
| Address |
At - VIP Road, Near Jhadeswari Temple, Puri - 2, Odisha
Head of Department, Kayachikitsa (Medicine), Room no. 6, Gopabandhu Ayurveda Mahavidyalaya, Puri
Puri ORISSA 752002 India |
| Phone |
9437199477 |
| Fax |
|
| Email |
prinicipalgampuri@gmail.com |
|
Details of Contact Person Public Query
|
| Name |
ProfDrSudarsan Behera |
| Designation |
Principal and H.O.D., Kayachiktsa |
| Affiliation |
Gopabandhu Ayurveda Mahavidyalaya, Puri |
| Address |
At - VIP Road, Near Jhadeswari Temple, Puri - 2, Odisha, Head of Department, Kayachiktsa(Medicine) , Room no. 6, Gopabandhu Ayurveda Mahavidyalaya, Puri
Puri ORISSA 752002 India |
| Phone |
9437199477 |
| Fax |
|
| Email |
prinicipalgampuri@gmail.com |
|
|
Source of Monetary or Material Support
|
| Harijiwan Pharmacy, At - Khadagali, Plot no. 446, Holding no. 114, P.O. - Rajgangpur, Dist - Sundergarh, Odisha, India |
|
|
Primary Sponsor
|
| Name |
Harijiwan Pharmacy |
| Address |
At - Khadagali, Plot no. 446, Holding no. 114, P.O. - Rajgangpur, Sundergarh |
| Type of Sponsor |
Pharmaceutical industry-Indian |
|
|
Details of Secondary Sponsor
|
|
|
Countries of Recruitment
|
India |
|
Sites of Study
|
| No of Sites = 1 |
| Name of Principal
Investigator |
Name of Site |
Site Address |
Phone/Fax/Email |
| ProfDr Sudarshan Behera |
Gopabandhu Ayurveda Mahavidyalaya, Puri |
OPD and IPD & Room no. 6 of Kayachikitsa (Medicine) Department, At - VIP Road, Near Jhadeswari Temple, Puri - 2, Odisha Puri ORISSA |
9437199477
prinicipalgampuri@gmail.com |
|
|
Details of Ethics Committee
|
| No of Ethics Committees= 1 |
| Name of Committee |
Approval Status |
| Institutional Ethical Committee, GAM, Puri |
Approved |
|
|
Regulatory Clearance Status from DCGI
|
|
|
Health Condition / Problems Studied
|
| Health Type |
Condition |
| Patients |
30 to 65 years patients with osteoarthritis, |
|
|
Intervention / Comparator Agent
|
| Type |
Name |
Details |
| Intervention |
Harijiwan Oil for external application |
Classical Ayurvedic Multidrug formulation for pain releif. Apply 5ml of the oil on the skin twice/ thrice daily as per severity of the case for 21 days. |
| Comparator Agent |
Not applicable |
Not applicable |
|
|
Inclusion Criteria
|
| Age From |
30.00 Year(s) |
| Age To |
65.00 Year(s) |
| Gender |
Both |
| Details |
1. All patients presenting with the clinical features of Osteoarthritis
2. Patients diagnosed to be suffering from osteoarthritis
3. Patients of Osteoarthritis who have gone for any type of treatment with or no sub optimal relief |
|
| ExclusionCriteria |
| Details |
1. Severe and complicated case of Osteoarthritis
2. Patient not complying the Direction of the Physician.
3. Any condition which can not be rendered as a case of O.A. |
|
|
Method of Generating Random Sequence
|
Not Applicable |
|
Method of Concealment
|
Case Record Numbers |
|
Blinding/Masking
|
Not Applicable |
|
Primary Outcome
|
| Outcome |
TimePoints |
| Reduction in joint pain related to O.A. and free movement of the joints. |
24 weeks |
|
|
Secondary Outcome
|
| Outcome |
TimePoints |
| Reduction in swelling of the joints |
14 weeks |
|
|
Target Sample Size
|
Total Sample Size="30" Sample Size from India="30"
Final Enrollment numbers achieved (Total)= "28"
Final Enrollment numbers achieved (India)="28" |
|
Phase of Trial
|
Phase 1 |
|
Date of First Enrollment (India)
|
01/06/2017 |
| Date of Study Completion (India) |
31/08/2017 |
| Date of First Enrollment (Global) |
Date Missing |
| Date of Study Completion (Global) |
Date Missing |
|
Estimated Duration of Trial
|
Years="0" Months="3" Days="0" |
|
Recruitment Status of Trial (Global)
|
Not Applicable |
| Recruitment Status of Trial (India) |
Completed |
|
Publication Details
|
None yet |
|
Individual Participant Data (IPD) Sharing Statement
|
Will individual participant data (IPD) be shared publicly (including data dictionaries)?
|
|
Brief Summary
|
The investigators are quite sure on the efficacy of Harijiwan Oil, a polyherbal oil containing garlic, clove, karpura, castor oil, black peeper, ajwain, nutmeg , pippali, cinnamomum, nilgiri oil sunthi and Dash mool in varied proportion; in the management of O.A. basing on the outcomes of the present study .The trial drug was found effective in improving all the signs and symptoms of OA. The mean scores of pain was reduced from 2.89 to 0.89, swelling reduced from 2.74 to 0.84, stiffness reduced from 2.70 to 0.74, crepitation reduced from 2.63 to 0.79, pain during extension and flexion reduced from 2.82 to 0.89, and tenderness reduced from 2.69 to 0.96. The mean overall score reduced from 15.61 to 4.86. All the above mentioned changes were found extremely significant statistically with p<0.0001. The overall rating of the product , we got good results in 78.87% cases, Excellent result in 14.29% cases and moderate result in 7.14% cases. Therefore only mild cases of O.A. should be prescribed for oil message, but moderate and severe to chronic cases should be prescribed with oral anti-arthritic drugs for better results. |